Holen Sie sich die Stockscreener-App
22.15
1.00%
0.22
Handel nachbörslich:
22.42
0.27
+1.22%
Schlusskurs vom Vortag:
$21.93
Offen:
$22
24-Stunden-Volumen:
1.50M
Relative Volume:
0.96
Marktkapitalisierung:
$2.21B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-183.79M
KGV:
-10.71
EPS:
-2.0691
Netto-Cashflow:
$-131.84M
1W Leistung:
+5.38%
1M Leistung:
+22.65%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$21.46
$22.20
1-Wochen-Bereich:
$20.41
$23.04
52-Wochen-Spanne:
$14.62
$23.04
Definium Therapeutics Inc Stock (DFTX) Company Profile
Firmenname
Definium Therapeutics Inc
Sektor
Branche
Telefon
212-220-6633
Adresse
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
22.15 | 2.19B | 0 | -183.79M | -131.84M | -2.0691 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Piper Sandler | Overweight |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-30 | Eingeleitet | Jefferies | Buy |
| 2025-10-13 | Eingeleitet | Needham | Buy |
| 2025-08-04 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-01-28 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-07-24 | Eingeleitet | ROTH MKM | Buy |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-12-09 | Fortgesetzt | ROTH Capital | Buy |
| 2022-11-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-26 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Eingeleitet | ROTH Capital | Buy |
| 2021-06-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Definium Therapeutics Inc Aktie (DFTX) Neueste Nachrichten
Definium Therapeutics (DFTX) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics Sees Insider Stock Selling - 富途牛牛
DFTX: Definium Therapeutics, Inc.Income Statment - Zacks Investment Research
All News for DFTX : Definium Therapeutics, Inc. - Zacks Investment Research
symbol__ Stock Quote Price and Forecast - CNN
DFTX: Piper Sandler Initiates Coverage with Overweight Rating | - GuruFocus
Definium Therapeutics stock hits 52-week high at 21.99 USD - Investing.com
Definium Therapeutics stock hits 52-week high at 21.99 USD By Investing.com - Investing.com UK
Piper Sandler Initiates Definium Therapeutics at Overweight - marketscreener.com
Piper Sandler initiates Definium stock with Overweight rating By Investing.com - Investing.com South Africa
Piper Sandler initiates Definium stock with Overweight rating - Investing.com UK
Investment bank Piper Sandler announced the official initiation of coverage on biopharmaceutical company Definium Therapeutics Inc, assigning it an "Overweight" rating. - Bitget
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events - marketscreener.com
Definium Therapeutics Inc (DFTX) Stock Price Quote Today & Current Price Chart | Capital.com UAE - Capital.com
Definium Therapeutics, Inc. (DFTX) stock price, news, quote and history - Yahoo Finance UK
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Price performance - Yahoo Finance Singapore
Do Definium Therapeutics’ (DFTX) New Hires Hint At A Deeper Bet On Anxiety Treatments? - Sahm
Can Definium Therapeutics (DFTX) Turn GAD Prevalence And DT120 Breakthrough Status Into Durable Advantage? - Yahoo Finance
Total non-current liabilities of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView — Track All Markets
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX) and Eli Lilly & Co (LLY) - The Globe and Mail
Definium Therapeutics stock hits 52-week high at 19.78 USD By Investing.com - Investing.com Canada
Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week HighHere's Why - MarketBeat
Definium Therapeutics stock hits 52-week high at 19.78 USD - Investing.com
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States - BioSpace
Definium Therapeutics (DFTX) Study Highlights Rising GAD Rates i - GuruFocus
Anxiety disorder prevalence rises to 6.6% in U.S., study finds By Investing.com - Investing.com Australia
Anxiety disorder prevalence rises to 6.6% in U.S., study finds - Investing.com
Definium Therapeutics Inc (DFTX) Stock Price Quote Today & Current Price Chart - Capital.com
Definium Therapeutics Inc (DFTX) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com
Definium Therapeutics Announces New Employee Inducement Grants - The Norfolk Daily News
A Look At Definium Therapeutics (DFTX) Valuation As Investor Day Highlights Late Stage DT120 ODT Pipeline - Sahm
Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update - Defense World
Definium Therapeutics Insider Sold Shares Worth $451,241, According to a Recent SEC Filing - marketscreener.com
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026 - BioSpace
Definium Therapeutics CMO Karlin sells $148k in shares By Investing.com - Investing.com Australia
Definium Therapeutics CEO Barrow sells $451k in shares By Investing.com - Investing.com India
Finanzdaten der Definium Therapeutics Inc-Aktie (DFTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):